297 related articles for article (PubMed ID: 24029605)
21. Anti-angiogenic therapies for malignant pleural mesothelioma.
Ceresoli GL; Zucali PA
Expert Opin Investig Drugs; 2012 Jun; 21(6):833-44. PubMed ID: 22519641
[TBL] [Abstract][Full Text] [Related]
22. [Inhibition of tumor angiogenesis as a cancer treatment].
Verheul HM; Bom JB; Hoekman K; Pinedo HM
Ned Tijdschr Geneeskd; 1999 Jul; 143(30):1549-55. PubMed ID: 10443279
[TBL] [Abstract][Full Text] [Related]
23. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
24. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.
Brauer MJ; Zhuang G; Schmidt M; Yao J; Wu X; Kaminker JS; Jurinka SS; Kolumam G; Chung AS; Jubb A; Modrusan Z; Ozawa T; James CD; Phillips H; Haley B; Tam RN; Clermont AC; Cheng JH; Yang SX; Swain SM; Chen D; Scherer SJ; Koeppen H; Yeh RF; Yue P; Stephan JP; Hegde P; Ferrara N; Singh M; Bais C
Clin Cancer Res; 2013 Jul; 19(13):3681-92. PubMed ID: 23685835
[TBL] [Abstract][Full Text] [Related]
25. [Neoplasms and angiogenesis].
Lewy-Trenda I
Pol Merkur Lekarski; 2002 Sep; 13(75):225-8. PubMed ID: 12474576
[TBL] [Abstract][Full Text] [Related]
26. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
Ellis PM; Al-Saleh K
Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
[TBL] [Abstract][Full Text] [Related]
28. Anti-angiogenic therapies in cancer: achievements and open questions.
Ruegg C; Mutter N
Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
[TBL] [Abstract][Full Text] [Related]
29. Challenges for patient selection with VEGF inhibitors.
Longo R; Gasparini G
Cancer Chemother Pharmacol; 2007 Jul; 60(2):151-70. PubMed ID: 17370072
[TBL] [Abstract][Full Text] [Related]
30. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
31. Is VEGF a predictive biomarker to anti-angiogenic therapy?
Otrock ZK; Hatoum HA; Musallam KM; Awada AH; Shamseddine AI
Crit Rev Oncol Hematol; 2011 Aug; 79(2):103-11. PubMed ID: 20724177
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Ferrara N; Hillan KJ; Novotny W
Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
[TBL] [Abstract][Full Text] [Related]
33. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
34. Combination of anti-angiogenic therapy and virotherapy: arming oncolytic viruses with anti-angiogenic genes.
Tysome JR; Lemoine NR; Wang Y
Curr Opin Mol Ther; 2009 Dec; 11(6):664-9. PubMed ID: 20072943
[TBL] [Abstract][Full Text] [Related]
35. Angiogenesis in neuroendocrine tumors: therapeutic applications.
Scoazec JY
Neuroendocrinology; 2013; 97(1):45-56. PubMed ID: 22538258
[TBL] [Abstract][Full Text] [Related]
36. Angiogenesis and anti-angiogenic therapy in prostate cancer.
Mukherji D; Temraz S; Wehbe D; Shamseddine A
Crit Rev Oncol Hematol; 2013 Aug; 87(2):122-31. PubMed ID: 23375349
[TBL] [Abstract][Full Text] [Related]
37. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives.
Sun HC; Tang ZY
J Cancer Res Clin Oncol; 2004 Jun; 130(6):307-19. PubMed ID: 15034787
[TBL] [Abstract][Full Text] [Related]
38. Anti-angiogenic therapy against gastrointestinal tract cancers.
Iwasaki J; Nihira S
Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
[TBL] [Abstract][Full Text] [Related]
39. Ischemic vascular disease and solid cancers: opposing ends of the angiogenic spectrum?
Balasubramanian SP; Reed MW
Med Hypotheses; 2006; 67(6):1317-9. PubMed ID: 16828237
[TBL] [Abstract][Full Text] [Related]
40. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]